Market Place
Sourcing Support
Adiso Therapeutics publishes Phase 1 data on ADS051 in AJG
06 Mar 2025 //
PR NEWSWIRE
Adiso Therapeutics Announces Positive Topline Data from Phase 1b Study of ADS051
22 Oct 2023 //
PR NEWSWIRE
Adiso Therapeutics Expands Board of Directors with Appointment of Robert Lisicki
12 Oct 2023 //
PR NEWSWIRE
Adiso Therapeutics to Participate in Upcoming September Investor Conferences
07 Sep 2023 //
PR NEWSWIRE
Adiso Announces Publication of Compelling Preclinical Research on ADS051
13 Jul 2023 //
PR NEWSWIRE
Adiso Announces Publication in Journal of Clinical & Immunology the ADS032
06 Jul 2023 //
PR NEWSWIRE
Adiso completes Phase Ib MAD study of UC therapy
01 Jun 2023 //
CLINICAL TRIALS ARENA
Adiso Announces the Completion of a Phase 1b Ascending Dose Study of ADS051
31 May 2023 //
PR NEWSWIRE
Adiso Announces Participation at Healthruption Disruption Conference
31 Mar 2023 //
PR NEWSWIRE
Adiso Announces the Appointment of Srikar Guntaka, M.D., as Medical Director
09 Feb 2023 //
PR NEWSWIRE
Adiso Therapeutics` ADS024 Selected for Oral Presentation at 2022 DDW
19 May 2022 //
PRNEWSWIRE
Copyright © 2025 LePro PharmaCompass OPC Private Limited, All rights reserved.